In an unplanned post hoc subgroup analysis based on PD‐L1 expression levels on tumour cells at initial biopsy, a benefit in OS was not proven in the PD‐L1‐negative patients of the PACIFIC trial (Antonia et al., 2018). This evidence concerns the gene CD274 and neoplasm.